The Future of Drug Discovery

HIV Innovation Outsourcing Obesity Cancer Surgery Politics Wall-street Government Schizophrenia Science History Ethics Epilepsy Economics Aging Clinical trials Developing countries Epidemics Hypertension Insurance companies Intellectual property Investment Knowledge management Multiple Sclerosis Recombinant proteins Regulations Stroke Side effects Myocardial infarction Pipelines Venture capital Safety Regulation Imaging Alliances Switzerland Rheumatoid arthritis Hypercholesterolemia Tax incentives Evidence-based medicine Oncology Patents Cystic fibrosis Pharmacogenomics Antibodies Drug interactions Mergers Genetic screening Biologicals Diagnostics Drug Costs Huntington's Disease Data management Investors Translational Research Funding society ad Personalized medicine Genetic Diseases Alzheimer's disease Research & development Quality-Adjusted-Life-Year OTC Basic research Type 2 diabetes Public private partnerships Orphan disease Anamnesis NSCLC Genome sequencing ENCODE Drug companies Drug safety Marketers Risk aversion Cancer drugs NDAS Indications Drug targets Government Intervention Academia Biomarkers Generics WHO Companion Diagnostics Emerging-economies Angiogenesis DNA sequencing Global Market Obesity drugs Clinical Trial Design Biosimilars COPD Tumor growth Pharmaceutical sales Rare disease Electronic medical records Genotyping Risk-return Manufacturing Patent protection QALY NGO's Fragile X HIV-AIDS Somatic mutations Drug target identification Biotech Statins Kinase Inhibitors Pharmaceutics Efficacy Mergers&Acquisitions Neuropathic Pain Stock prices Big pharma Adverse Drug Reactions PD Drug price regulation Best in class Market capitalization Benefit-risk CROs Blockbusters Government Support Cost-benefit Orphan diseases acquired mutations Alzheimer disease research approved drugs Biotech Projects Stock Market biotechs cannabinoid receptor antagonists core therapeutic areas diagnostics regulation drug value cost-effective drugs Drug Consumption drug discovery failure rates disease prevalence drug prices evidence-based trials future drug development generic drug companies FDA expert panels global drug approval generic firms governmental intervention government investment government-sponsored clinical trials geopolitical drug development health-care budgets drug target validation Drug Market drug profitability INDs economic cost of disease inherited mutations large biotech industry trends market capitalizations medical need evidence-based medicine trials me-toos generic companies patent guidelines guaranteed markets not-for-profit pharma companies phase 3 failures number to treat off-label drug use future of drug discovery non-governmental research Product Development Cycle product specialization patient groups post marketing surveillance responder rate proprietary drugs quality & credibility spin-out companies responder groups small pharma lower growth single-point mutations small biotech societal intervention societal stability therapeutic areas toaster drugs untreated diseases large indications WHI Study Virtual Companies targeted cancer therapies new medicines knowledge mining phase 2 candidates point of care metrics mutated enzymes new disease creation preventative trials nongovernmental organizations medical care costs R&D spending R&D future regulatory bodies strategic vacuum phase 2 drugs Unmet needs preventative drugs profit margins protein fingerprinting R&D cuts Stock Market Analysts the Patient Protection and Affordable Care Act treated diseases mergers & acquisitions